PRESS RELEASE

The Gene Center at Ludwig-Maximilians-Universität München, Germany and ExpreS²ion Biotechnologies enter a licensing agreement for use of the ExpreS² technology platform

Hørsholm, Denmark, and Munich, Germany 2 February, 2015 – Biotech company ExpreS²ion Biotechnologies today announced the signature of a research license agreement to provide the Gene Center at Ludwig-Maximilians-Universität München with access to its *Drosophila* Schneider-2 cell-based technology platform - ExpreS² - for recombinant protein production. The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Gene Center. The platform will be used to address expression of complex and "challenging" proteins, including antibody fragments and other proteins.
This license fits with ExpreS²ion Biotechnologies' vision of making its protein expression system available to top academic centers globally, as one of the standard protein production platforms for research and development in the areas of immunotherapy and therapeutic proteins.

Dr. Charlotte Dyring, CEO of ExpreS²ion Biotechnologies, said: "We are excited to sign this license agreement with the Gene Center at Ludwig-Maximilians-Universität München, a center of excellence for research into genome maintenance and the regulation of gene expression at all levels. The ExpreS² protein expression system can respond effectively to the high demands in protein quality and quantity of structural biology projects, and it enables successful production of antibodies and antibody fragments that might fail to express in alternative systems. The Gene Center has been testing the ExpreS² system for protein production, with very satisfying results".

Professor Dr. Karl-Peter Hopfner, Professor at the Gene Center at Ludwig-Maximilians-Universität München commented: "We want to understand the molecular and structural mechanisms how the cellular DNA repair and antiviral RNA sensing protein machineries detect, signal and repair or remove malignant nucleic acids such as damaged DNA and viral RNA. The ExpreS² system complements our tool-box of protein expression systems successfully, allowing us to generate the proteins and antibody-based tools we require, to advance our research".

About ExpreS²ion Biotechnologies
ExpreS²ion Biotechnologies has developed a complete proprietary protein expression platform, ExpreS², based on engineered *Drosophila* Schneider-2 (S2) cells to serve recombinant protein production needs in the biopharmaceutical industry as well as in academia. ExpreS² allows quick access to proteins, including complex and multi-chain proteins, excellent protein expression capability, scalability, applicability to high cell density production processes and regulatory friendliness. ExpreS²ion Biotechnologies is collaborating with teams developing manufacturing

processes for subunit vaccines. Expression of notoriously challenging malaria proteins in ExpreS^2 platform has enabled progress in addressing a huge medical need.
ExpreS^{2}ion Biotechnologies offers technology platform licensing opportunities for use in R&D and commercial protein manufacturing. For more information visit www.expres2ionbio.com

About the Gene Center at Ludwig-Maximilians-Universität, München

The Gene Center is a central research facility of the LMU Munich that comprises the Department of Biochemistry, centrally funded junior groups, as well as members of the medical and veterinary faculties.

# # # #

Contact at ExpreS^{2}ion Biotechnologies:
Dr. Sancha Salgueiro
Tel: +45 4166 6121
Email: sas@expres2ionbio.com

Contact at the Gene Center, LMU:
Prof. Dr. Karl-Peter Hopfner
Tel: +49 (0) 89 2180 76953
Email: hopfner@genzentrum.lmu.de